When was BioArray Solutions founded?

BioArray Solutions was founded in 2001 and raised its 1st funding round 4 years after it was founded.

Where is BioArray Solutions located?

BioArray Solutions is headquartered in New York City, United States.

Who is the current CEO of BioArray Solutions?

Jeffrey Binder of BioArray Solutions.

How many employees does BioArray Solutions have?

As of Jul 31, 2026, the latest employee count at BioArray Solutions is 12.

Is BioArray Solutions a funded company?

BioArray Solutions is a funded company, having raised a total of $56.8M across 4 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jan 10, 2005.

When was the latest funding round of BioArray Solutions?

BioArray Solutions' latest funding was a $***** Series E round on 2007, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.23B in funding in 2026 to date.

Where does BioArray Solutions rank among its competitors?

BioArray Solutions ranks 33rd amongst 166 active competitors, of which 48 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was SonoThera, which secured $125M in Jun, 2026.

Who are the top competitors of BioArray Solutions?

BioArray Solutions' top competitors include Genedit, Portal and PathogenDX. Among them, SonoThera secured the most recent funding round in June, 2026.

BioArray Solutions - 2026 Company Profile, Team, Funding & Competitors

Company Details

Bioarray solutions focuses on developing bead-based assays for nucleic acid and protein analysis.It has also developed products for genetic diagnostics and infectious disease agent profiling, and, FDA clearance for an autoantibody profiling ("ENA") BeadChip™ assay on its Array Imaging System. Its BeadChip(TM) system deploys planar arrays of proprietary encoded microparticles to perform rapid and reliable molecular analysis of nucleic acids and proteins.The company was acquired by Immucor in March, 2008.

Key Metrics

Founded Year

2001

Location

New York City, United States

Stage

Acquired

Total Funding

$56.8M in 4 rounds

Latest Funding Round

Series E, 2007, $*****

Investors

Axiom Venture Partners & 1 more

Ranked

33^rd among 166 active competitors

Employee Count

12 as on Jul 31, 2026

Similar Companies

Genedit & 225 more

Exit Details

Acquired by Immucor (Mar 11, 2008)

View BioArray Solutions' full profile

BioArray Solutions got acquired by Immucor on Mar 11, 2008.

Click here to take a look at BioArray Solutions's acquisition in detail

BioArray Solutions has raised a total funding of $56.8M over 4 rounds. Its first funding round was on Jan 10, 2005. Its latest funding round was a Series E round on 2007 for $*****. 1 investor participated in its latest round. BioArray Solutions has 2 institutional investors.

Here is the list of recent funding rounds of BioArray Solutions:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2007	2174	Series E	2764	3055	5250	4007
2006	5719	Series D	4270	5263	6787	NGN Capital
Jun 13, 2005	3746024	Series B	1209957	6809859	9313815	1054335

Access funding benchmarks and valuations. Sign up today!

View details of BioArray Solutions's funding rounds and investors

BioArray Solutions' employee count trend

BioArray Solutions has 12 employees as of Jul 26. Here is BioArray Solutions's employee count trend over the years:

Employee count trend for BioArray Solutions

Uncover BioArray Solutions' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioArray Solutions include Genedit, Portal and PathogenDX. Here is the list of Top 10 competitors of BioArray Solutions, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, DCVC & 20 others	65/100
2nd	Portal 2023, Watertown (United States), Seed	Provider of cell engineering and cell analytics across research and clinical applications	$25.7M	NFX, IA Ventures & 7 others	61/100
3rd	PathogenDX 2014, Tucson (United States), Series B	Provider of DNA-based pathogen testing kits	$11.6M	Entourage Effect Capital, Altitude Investment Management ... & 11 others	61/100
4th	Agendia 2003, Irvine (United States), Series F	Provider of genomic diagnostic products for the treatment of cancer	$123M	Athyrium Capital Management, Van Herk Groep ... & 9 others	59/100
5th	Genenta Science 2014, Milan (Italy), Public	Developer of lentivirus-based gene and cell therapies for cancer	$33.6M	Mediobanca, Qianzhan & 4 others	59/100
6th	SonoThera 2022, San Francisco (United States), Series B	Developer of nonviral gene therapies for genetic diseases	$186M	Arch Venture Partners, Vida Ventures & 21 others	57/100
7th	InDevR 2003, Boulder (United States), Acquired	Manufacturer of biotherapeutics, vaccines and diagnostic products	$16M	Adjuvant Capital, BioMerieux & 2 others	57/100
8th	Candel Therapeutics 1999, United States, Public	Developer of viral immunotherapies for the treatment of cancer	$81.6M	PBM Capital, B. Riley Wealth Management & 4 others	57/100
9th	LogicBio 2013, Lexington (United States), Acquired	Developer of viral vectors for the treatment of genetic and infectious diseases	$49M	Arix Bioscience, Orbimed & 6 others	57/100
10th	KromaTiD 2007, Fort Collins (United States), Series C	Provider of molecular and genetic tests for detection of disease-causing mutations	$15.4M	Broadoak Capital Partners, First Capital Ventures ... & 5 others	56/100
33rd	BioArray Solutions 2001, New York City (United States), Acquired	Beadchip for biomolecular analysis	$56.8M	Axiom Venture Partners, NGN Capital	42/100